Last reviewed · How we verify
oral antipsychotic medication
Blocks dopamine receptors in the brain to help manage psychosis symptoms.
Blocks dopamine receptors in the brain to help manage psychosis symptoms. Used for Treatment of schizophrenia, Treatment of bipolar disorder.
At a glance
| Generic name | oral antipsychotic medication |
|---|---|
| Sponsor | US Department of Veterans Affairs |
| Drug class | oral antipsychotic |
| Target | Dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Oral antipsychotic medications like this one work by blocking dopamine receptors in the brain, which helps to reduce symptoms of psychosis such as hallucinations and delusions. This can help improve mood and cognitive function in individuals with schizophrenia and other mental health conditions.
Approved indications
- Treatment of schizophrenia
- Treatment of bipolar disorder
Common side effects
- Weight gain
- Dizziness
- Headache
- Nausea
- Fatigue
Key clinical trials
- Cue-based Intervention in Prospective Memory and Medication Adherence. (NA)
- Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder (PHASE2)
- Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia (PHASE3)
- CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia (PHASE3)
- Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities (PHASE4)
- Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms (NA)
- Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia (PHASE3)
- Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oral antipsychotic medication CI brief — competitive landscape report
- oral antipsychotic medication updates RSS · CI watch RSS
- US Department of Veterans Affairs portfolio CI